Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study

Pharmacogenetics and Genomics

Volumn 27, Issue 1, 2017, Pages 1-6

  Bousman, Chad A ^a,b   Müller, Daniel J ^e,f   Ng, Chee H ^a   Byron, Keith ^c   Berk, Michael ^a,d   Singh, Ajeet B ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c Healthscope Pathology ^*  (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Desvenlafaxine; Major depression; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Precision medicine

Indexed keywords

DESVENLAFAXINE; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; UGT1A1 ENZYME;

ADULT; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SENSITIVITY AND SPECIFICITY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; GENETICS; METABOLISM; MIDDLE AGED; PHARMACOGENETIC VARIANT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DESVENLAFAXINE SUCCINATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PHARMACOGENOMIC VARIANTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84992350032     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000253     Document Type: Article

References (35)

1. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014; 27:43-51.
2. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473.
3. Muller DJ, Kekin I, Kao AC, Brandl EJ. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 2013; 25:554-571.
4. Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98:127-134.
5. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15:209-217.
6. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93:402-408.
7. Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3:585-590.
8. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25:423-429.
9. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29:39-43.
10. Baird-Bellaire S, Behrle JA, Parker VD, Patat A, Paul J, Nichols AI. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther 2013; 35:782-794.
11. Shin HJ, Kim JY, Cheong HS, Na HS, Shin HD, Chung MW. Functional study of haplotypes in UGT1A1 promoter to find a novel genetic variant leading to reduced gene expression. Ther Drug Monit 2015; 37:369-374.
12. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 2010; 20:632-640.
13. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:398-404.
14. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57:203-209.
15. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011; 21:163-170.
16. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2012; 2:e198.
17. Lee SH, Lee MS, Lee JH, Kim SW, Kang RH, Choi MJ, et al. MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol 2010; 30:116-125.
18. Breitenstein B, Scheuer S, Bruckl TM, Meyer J, Ising M, Uhr M, Holsboer F. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res 2015; 73:86-95.
19. Breitenstein B, Bruckl TM, Ising B, Müller-Myhsok M, Holsboer F, Czamara D. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015; 168B:274-283.
20. Jelen AM, Salagacka A, Zebrowska MK, Mirowski M, Talarowska M, Gałecki P, Balcerczak EI. The influence of C3435T polymorphism of the ABCB1 gene on genetic susceptibility to depression and treatment response in Polish population - preliminary report. Int J Med Sci 2015; 12:974-979.
21. Chang HH, Chou CH, Yang YK, Lee IH, Chen PO. Association between ABCB1 polymorphisms and antidepressant treatment response in Taiwanese major depressive patients. Clin Psychopharmacol Neurosci 2015; 13:250-255.
22. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 2015; 13:150-156.
23. Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J 2011; 26:77-83.
24. Tsai HH, Lin HW, Simon Pickard A, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract 2012; 66:1056-1078.
25. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012; 26:959-973.
26. Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J 2013; 15:1242-1252.
27. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003; 307:262-267.
28. MIMS Australia. 2016. Desvenlafaxine. Available at: http://www.mims.com. au. [Accessed 2 August 2016].
29. Riedel M, Moller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adi M, et al. Response and remission criteria in major depression - a validation of current practice. J Psychiatr Res 2010; 44:1063-1068.
30. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform 2014; 48:193-204.
31. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009; 11:216-225.
32. Altar CA, Carhart JM, Allen JD, Hall-Flavin D, Dechairo BM, Winner JG. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 2015; 15:443-451.
33. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68:677-688.
34. Liu W, Ramirez J, Gamazon ER, Mirkov S, Chen P, Wu K, et al. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 2014; 23:5558-5569.
35. Dodd S, Berk M. Predictors of antidepressant response: a selective review. Int J Psychiatry Clin Pract 2004; 8:91-100.